Intra-Cellular Therapies is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. Intra-Cellular Therapies is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.

Employee Rating

0More
TypePublic
HQNew York, US
Founded2002
Size (employees)49 (est)+20%
Websiteintracellulartherapies.com
Intra-Cellular Therapies was founded in 2002 and is headquartered in New York, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, (HQ)
900 430 E 29th St
Show all (1)
Report incorrect company information

Intra-Cellular Therapies Financials and Metrics

Intra-Cellular Therapies Revenue

Intra-Cellular Therapies's revenue was reported to be $245.84 k in FY, 2017
USD

Net income (Q2, 2018)

(72.9m)

EBIT (Q2, 2018)

(76.3m)

Market capitalization (4-Dec-2018)

756.3m

Closing stock price (4-Dec-2018)

13.8

Cash (30-Jun-2018)

69.8m
Intra-Cellular Therapies's current market capitalization is $756.3 m.
Annual
USDFY, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.7m2.7m577.3k91.4k330.7k245.8k

Revenue growth, %

(79%)(84%)262%

General and administrative expense

6.0m10.3m18.2m24.8m23.7m

R&D expense

23.0m21.2m87.7m93.8m79.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

668.0k167.8k219.2k124.4k3.3k57.4k124.4k3.3k228.4k4.4k95.3k114.7k30.8k

General and administrative expense

1.3m1.9m2.1m2.6m3.8m4.0m3.9m5.1m6.5m6.3m6.3m6.3m5.3m6.4m13.1m

R&D expense

4.2m2.8m2.7m4.0m18.6m17.8m28.5m23.4m25.3m23.9m21.5m12.5m18.5m30.7m63.1m

Operating expense total

5.5m4.7m4.8m6.6m22.4m21.7m32.3m28.5m31.8m30.2m27.8m18.7m23.8m37.1m76.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

35.2m61.3m47.2m48.6m37.8m

Accounts Receivable

336.3k51.6k30.7k94.3k

Inventories

762.2k1.3m8.0m4.0m

Current Assets

38.2m131.0m483.3m388.2m469.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

44.1m143.6m91.1m68.9m100.8m71.4m332.8m37.2m52.0m200.4m23.6m29.6m52.3m74.4m69.8m

Accounts Receivable

251.3k167.8k219.2k124.4k3.3k9.1k51.6k98.2k1.3k68.2k61.9k6.3k

Current Assets

47.1m146.4m141.2m137.5m236.5m212.6m512.3m462.9m446.8m541.8m371.6m348.8m333.4m443.2m409.7m

PP&E

75.7k65.1k63.9k57.4k559.7k722.1k785.5k731.4k718.7k677.7k605.7k628.9k679.6k1.3m1.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)

Depreciation and Amortization

23.2k25.5k139.6k196.9k213.9k

Inventories

Accounts Payable

3.4m(1.3m)(419.9k)2.1m2.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(4.9m)(4.5m)(9.1m)(6.4m)(22.3m)(43.8m)(32.2m)(27.8m)(58.7m)(88.9m)(26.9m)(44.7m)(67.6m)(35.5m)(72.9m)

Depreciation and Amortization

6.3k12.7k47.1k48.0k96.7k146.8k50.4k101.8k155.3k82.5k178.3k

Accounts Payable

(1.3m)(3.0m)503.9k4.6m2.9m705.0k326.4k2.3m3.8m3.4m(2.0m)653.0k3.9m(794.7k)

Cash From Operating Activities

(7.0m)(12.2m)(46.7m)(19.7m)(33.1m)(62.8m)(16.4m)(41.3m)(55.7m)(27.0m)(60.6m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Show all operating metrics

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Report incorrect company information

Intra-Cellular Therapies News and Updates

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter …

Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease

Results show ITI-214 is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias             

Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Mark Neumann as Executive Vice President, Chief Commercial…
Report incorrect company information

Intra-Cellular Therapies Company Life and Culture

Report incorrect company information

Intra-Cellular Therapies Frequently Asked Questions

  • When was Intra-Cellular Therapies founded?

    Intra-Cellular Therapies was founded in 2002.

  • How many employees does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 49 employees.

  • What is Intra-Cellular Therapies revenue?

    Latest Intra-Cellular Therapies annual revenue is $245.8 k.

  • What is Intra-Cellular Therapies revenue per employee?

    Latest Intra-Cellular Therapies revenue per employee is $5 k.

  • Who are Intra-Cellular Therapies competitors?

    Competitors of Intra-Cellular Therapies include Microbion, Charles River Laboratories International and Hancock Jaffe.

  • Where is Intra-Cellular Therapies headquarters?

    Intra-Cellular Therapies headquarters is located at 900 430 E 29th St, New York.

  • Where are Intra-Cellular Therapies offices?

    Intra-Cellular Therapies has an office in New York.

  • How many offices does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 1 office.